FIELD: medicine.
SUBSTANCE: invention refers to medicine. The method implies measuring a waist circumference (WC), height and weight for calculating the body weight index (BWI), blood pressure (PB), and measuring glucose and lipids. If WC is more than 80 cm, while BWI is more than 25 kg/m2, a mild hypocaloric diet is used, which is limiting the caloric content of the dietary intake by 500-600 kcal a day with the daily dietary intake being drawn up taking into account as follows: total fat consumption of less than 30% of the total caloric content; carbohydrates - up to 50%; the protein content in the food intake - 15-20%; dietary fibre - 20-30 mg; fresh fruit and vegetables - 400-500 g; nuts, cereals and beans - 30 g; table salt - less than 5 g; calcium 1,200 mg a day; vitamin D - 800 international units, polysaturated fatty acids 0.5-1.0 g, folic acid 400 mcg, vitamin C 60 mcg, vitamin E 30 units; physical load - not less than 40 min a day and at least 5 days a week; alternating aerobic and anaerobic exercises. Additionally, if BWI falls within the range of 25 to 29.9 kg/m2 with normal glucose, lipids and blood pressure, combined oral contraceptives (COC) containing natural oestrogen and dienogest, or COC containing drospiredone are used. If BWI is more than 30 kg/m2, with normal glucose, blood pressure and lipid, pure progestin oral contraceptives (PPOC) are taken. If observing BWI of 25 kg/m2 and more, fasting hyperglycaemia and/or impaired glucose tolerance, and normal blood pressure and lipids, the PPOC are prescribed. BWI of 25 to 29.9 kg/m2, as well as dyslipidemia and normal glucose and lipids, the combined oral contraceptives (COC) containing natural oestrogen and dienogest are prescribed. If observing BWI of 30 kg/m2 and more, dyslipidemia and normal glucose and lipids, the PPOC are prescribed.
EFFECT: method enables the patient-specific prevention of the oestrogen-dependent diseases.
10 cl, 2 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR INDIVIDUAL PREVENTION OF OESTROGEN-DEPENDENT DISEASES AND REPRODUCTIVE DISORDERS IN FEMALES AT AGE OF 18-35 YEARS OLD SUFFERING METABOLIC DISORDERS | 2013 |
|
RU2527358C1 |
METHOD FOR INDIVIDUAL PREVENTION OF OESTROGEN-DEPENDENT DISEASES IN HEALTHY FEMALES AND FEMALES SUFFERING CARDIOVASCULAR RISK FACTORS AT AGE OF 45-60 YEARS OLD | 2013 |
|
RU2527357C1 |
METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
METHOD FOR CORRECTION OF DYSLIPIDEMIA IN WOMEN WITH METABOLIC SYNDROME DURING MENOPAUSAL TRANSITION | 2021 |
|
RU2771426C1 |
METHOD FOR INSULIN RESISTANCE CORRECTION IN METABOLIC SYNDROME | 2009 |
|
RU2402326C1 |
METHOD OF OBESITY TREATMENT | 2008 |
|
RU2354360C1 |
METHOD OF TREATING EXTERNAL GENITAL ENDOMETRIOSIS | 2019 |
|
RU2727299C1 |
METHOD OF TREATING PATIENTS WITH METABOLIC SYNDROME | 2019 |
|
RU2706385C1 |
METHOD OF CHOOSING THERAPEUTIC APPROACH IN MENSTRUAL DISORDERS IN ADOLESCENT GIRLS WITH OVERWEIGHT | 2010 |
|
RU2422824C1 |
METHOD OF TREATING ABDOMINAL OBESITY IN CASE OF METABOLIC SYNDROME | 2013 |
|
RU2548709C1 |
Authors
Dates
2014-12-27—Published
2013-08-02—Filed